Skip to content

Preclinical small sample trial of Congrong Shujing Granules for Parkinson's disease: a randomized, triple-blind, parallel-controlled

Development of six new drugs of Congrong Shujing Granules against myotonic in Parkinson's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003428
Enrollment
Unknown
Registered
2020-06-24
Start date
2020-07-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Sponsors

Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of PD and 1-3 grading criteria; 2. Patients aged 45-80 years; 3. If the patient is treated with anti PD drugs, the dose is stable for at least 30 days; 4. Patients can cooperate with all examinations, tests, questionnaires, etc. required by the study (such as long-term Mrs examination); 5. Patients who voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. MRI was performed in patients with intracranial organic lesions; 2. Patients with limb trauma, neuromuscular junction and muscle diseases, diabetic peripheral neuropathy, rheumatism and immunity can lead to systemic diseases of peripheral neuropathy; 3. Patients with major diseases such as severe heart, liver and kidney dysfunction, mental and neurological diseases, severe infection, tumor, etc.; 4. The allergic constitution is allergic to the known related traditional Chinese medicine ingredients; 5. Patients who have ever been treated with traditional Chinese medicine or proprietary Chinese medicine for PD symptoms, and the time interval between the last medication and this visit is less than 7 days; 6. Patients who have received deep brain stimulation; 7. Patients who cannot complete the examination due to other diseases; 8. Patients who participated in other clinical trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale;

Secondary

MeasureTime frame
relevant indicators of 1H-MRS examination;relevant indicators of Emg somatosensory evoked potential;

Countries

China

Contacts

Public ContactCai Jing

Fujian University of Traditional Chinese Medicine

caij1@163.com+86 13110770937

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026